# A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin

> **NCT01218204** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 287 (actual)

## Conditions studied

- Dyslipidaemias
- Dyslipidemias

## Interventions

- **DRUG:** 10mg atorvastatin
- **DRUG:** 80mg atorvastatin
- **DRUG:** GSK1292263 Placebo
- **DRUG:** 100mg GSK1292263
- **DRUG:** 300mg GSK1292263
- **DRUG:** 800mg GSK1292263
- **DRUG:** 10mg ezetimibe
- **OTHER:** Washout

## Key facts

- **NCT ID:** NCT01218204
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09-14
- **Primary completion:** 2011-06-29
- **Final completion:** 2011-06-29
- **Target enrollment:** 287 (ACTUAL)
- **Last updated:** 2019-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01218204

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01218204, "A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01218204. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*